SSGJ-707 is a bispecific, recombinant humanized IgG4 monoclonal antibody inhibitor targeting PD-1 and VEGF. SSGJ-707 can be used for cancers research, such as advanced non-small cell lung cancer (NSCLC) and recurrent endometrial cancer[1]
Molecular Weight:
(241.16 kDa)
Purity:
99
Target:
PD-1/PD-L1,VEGFR
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
